Arch Biopartners Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACHFF research report →
Price Chart
About the company
Arch Biopartners Inc. is a biotechnology company focused on developing innovative technologies with significant medical and commercial potential. Their primary endeavor involves advancing Metablok, a lead drug candidate designed to treat or prevent dipeptidase-1 (DPEP-1) mediated inflammation in critical organs like the lungs, liver, and kidneys.
- CEO
- Richard Gabriel Muruve
- IPO
- 2002
- Employees
- 6
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on ACHFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $39.33M
- P/E
- -19.76
- PEG
- 0.31
- P/S
- 0.00
- P/B
- -14.32
- EV/EBITDA
- -23.14
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 74.79%
- ROIC
- 206.08%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-1,499,812
- Net Income
- $-1,552,744+60.4%
- EPS
- $-0.02+61.7%
- OCF Growth
- +32.0%
- FCF Growth
- +32.0%
- 52W High
- $1.02
- 52W Low
- $0.29
- 50D MA
- $0.67
- 200D MA
- $0.58
- Beta
- 1.58
- RSI (14)
- 43
- Avg Volume
- 19.55K
No earnings-call transcripts are available for ACHFF yet.
- Free Float
- 78.2%
- Shares Outstanding
- 67.93M
- Float Shares
- 53.11M
Our ACHFF coverage
Recent articles, reports, and earnings notes.
No research on ACHFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACHFF report →Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
globenewswire.com · Aug 31
Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program
globenewswire.com · Jul 17
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
globenewswire.com · Jul 8
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
globenewswire.com · Jun 4
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
globenewswire.com · May 22
Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI
globenewswire.com · Apr 30
Arch Biopartners Closes Non-Brokered Private Placement
globenewswire.com · Apr 2
Arch Biopartners Arranges Non-Brokered Private Placement
globenewswire.com · Mar 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.